EVAXION BIOTECH A/S

(EVAX)
  Rapporto
Tempo differito Nasdaq  -  16:19 09/08/2022
2.811 USD   -3.07%
02/08Evaxion Biotech dice che l'amministratore delegato si dimette, Per Norlen viene nominato come sostituto; le azioni calano
MT
02/08Evaxion Biotech A/S annuncia cambiamenti nel management esecutivo
CI
01/07Evaxion Biotech A/S annuncia di essere pronta per il reclutamento per lo studio clinico Evx-01 di Fase 2B
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su EVAXION BIOTECH A/S
02/08Evaxion Biotech Says CEO Resigns, Per Norlen Named as Replacement; Shares Drop
02/08EVAXION BIOTECH A/S: Announces Executive Management Changes - Form 6-K
02/08Evaxion Biotech A/S Announces Executive Management Changes 
02/08Evaxion Biotech A/S Announces Executive Management Changes 
02/08Evaxion Biotech A/S Announces Executive Management Changes
29/07Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10
08/07BIOSTOCK: Evaxion Biotech expands its programme with a new indication
01/07Evaxion Biotech A/S Announces That It Is Ready for Recruitment for the Evx-01 Phase 2B ..
30/06Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
30/06Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
30/06Evaxion Biotech A/S Announces Gonorrhea as Second Bacterial Product Target
23/06Evaxion Biotech to Target Non-Small Cell Lung Cancer With Drug Candidate; Shares Rise P..
23/06EVAXION BIOTECH A/S: Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Canc..
23/06Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
23/06Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
23/06Evaxion Biotech Expands its EVX-03 DNA Vaccine Program into Non-Small Cell Lung Cancer
10/06BIOSTOCK: Evaxion Biotech Secures Equity Financing of up to 40 MUSD
07/06EVAXION BIOTECH A/S: Secures Equity Financing of up to $40 Million from Lincoln Park Capi..
07/06Evaxion Biotech Says it has Secured Up To $40 Million in Equity Financing From Lincoln ..
07/06Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
07/06Evaxion Biotech A/S announced that it expects to receive $40 million in funding from Li..
19/05Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Boar..
17/05European ADRs Move Higher in Tuesday Trading
16/05European ADRs Move Higher in Monday Trading
16/05BIOSTOCK: Evaxion Biotech shows strong clinical momentum in Q1
12/05European ADRs Decline in Thursday Trading
11/05TRANSCRIPT: Evaxion Biotech A/S, Q1 2022 Earnings Call, May 11, 2022
11/05Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Up..
11/05Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Up..
11/05Evaxion Biotech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
10/05SECTOR UPDATE: Health Care Stocks Still Edging Higher This Afternoon
10/05Wall Street Set for Recovery After Monday's Sell-Off
10/05Top Premarket Gainers
10/05Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies ..
10/05Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies ..
10/05Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies ..
10/05Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies ..
29/04Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11
26/04Evaxion Biotech to Use Personalis Platform to Evaluate Efficacy of Skin Cancer Combinat..
12/04EVAXION BIOTECH A/S: COMPLETE PROPOSALS - Form 6-K
12/04TRANSCRIPT: Evaxion Biotech A/S - Special Call
06/04Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personali..
05/04Evaxion Biotech A/S Announces Executive Changes
01/04EVAXION BIOTECH A/S: Annual Report by Foreign Issuer (Form 20-F)
22/03TRANSCRIPT: Evaxion Biotech A/S, Q4 2021 Earnings Call, Mar 22, 2022
22/03EVAXION BIOTECH A/S: Announces Fourth Quarter and Full Year 2021 Financial Results and Pr..
22/03Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provi..
22/03Evaxion Biotech A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended..
15/03EVAXION BIOTECH A/S: Strengthens Management Team with Two Senior Appointments - Form 6-K
15/03BIOSTOCK: Evaxion completes EVX-02 clinical trial recruitment
14/03Evaxion Biotech Appoints CFO, COO
14/03Evaxion Biotech Strengthens Management Team with Two Senior Appointments
14/03Evaxion Biotech A/S Appoints Bo Karmark as its Chief Financial Officer
14/03Evaxion Biotech A/S Appoints Jesper Nyegaard Nissen as its Chief Operating Officer
07/03EVAXION BIOTECH A/S: Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02 - For..
07/03Evaxion Biotech Completes Recruitment For Phase 1/2a Trial of EVX-02 in Adjuvant Melano..
07/03Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
07/03Evaxion Biotech A/S Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
09/02BIOSTOCK: Evaxion Biotech publishes EVX-01 data in scientific journal OncoImmunology
26/01Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b ..
26/01Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b ..
24/01BIOSTOCK: Evaxion Biotech gets a go-ahead for phase IIb with EVX-01
18/01EVAXION BIOTECH A/S: Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in..
18/01Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Co..
18/01Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Co..
2021BIOSTOCK: Capital injection sets Evaxion Biotech up for phase IIb trials
2021EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEME..
2021Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including..
2021Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including..
2021Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update - Form..
2021Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
2021Evaxion Biotech A/S Reports Earnings Results for the Third Quarter and Nine Months Ende..
2021Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering - Form 6-K
2021Top Premarket Decliners
2021Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
1  2Succ.
Prossimo evento su EVAXION BIOTECH A/S